CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following
CN Bio to provide drug metabolism and safety toxicity testing services
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell
CN Bio and Imperial College London Collaboration
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis. CN Bio’s Liver-on-Chip technology to define
CN Bio makes key senior appointments to support international commercial development
Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis
CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
Investment will support commercial development in key markets, US and Europe Funding led by CITIC Securities Investment and supported by
NASH drug discovery service launched at AASLD
Leading bioengineering company CN Bio has launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic
Sydney’s AXT offers Organ-on-Chip systems in Asia Pacific region
Organ-on-Chip specialist CN Bio has signed a distribution agreement with Sydney-based AXT Pty. Ltd., Australia’s leading supplier of high technology
CN Bio to bring 10 organs together on a chip
London Organ-on-Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of